Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice

Young Sun Kang, Mi Hwa Lee, Hye Kyoung Song, Jung Eun Kim, Jung Yeon Ghee, Jin Joo Cha, Ji Eun Lee, Hyun Wook Kim, Jee Young Han, Dae-Ryong Cha

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: Visfatin is a known adipokine which may improve insulin resistance in obesity and have an anti-diabetic effect via the insulin receptor. We studied the effects of visfatin on diabetic nephropathy in type 2 diabetic mice. Methods: Diabetic male db/db mice were treated with intraperitoneal injections of visfatin. Basal parameters were measured in all mice and glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed in diabetic mice. The histopathological and molecular changes were evaluated in diabetic nephropathy. Results: Visfatin treatment had no effect on body weight, water and food intake, urinary volume, blood glucose, and HbA1c level. However, visfatin improved HOMA-IR, GTT, ITT and decreased plasma insulin and visfatin level, but not adiponectin level. Plasma cholesterol and triglyceride level were also improved by visfatin treatment. Significantly, visfatin decreased albuminuria in diabetic mice. Glomerulosclerotic change and mesangial expansion in the kidneys were significantly reduced. In addition, visfatin inhibited the expression of proinflammatory and profibrotic cytokines such as MCP-1, TGFβ1, type IV collagen, and PAI-1. The enzymes related to lipid metabolism in the kidney, HMG-CoAR was suppressed by visfatin treatment, whereas FXR and ABCA1 were significantly elevated by treatment. Conclusion: Visfatin might have a protective effect in diabetic nephropathy without the hypoglycemic effect.

Original languageEnglish
Pages (from-to)311-324
Number of pages14
JournalKidney and Blood Pressure Research
Volume41
Issue number3
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Nicotinamide Phosphoribosyltransferase
Diabetic Nephropathies
Insulin
Glucose Tolerance Test
Kidney
Adipokines
Albuminuria
Collagen Type IV
Body Water
Adiponectin
Plasminogen Activator Inhibitor 1
Insulin Receptor
Therapeutics
Intraperitoneal Injections
Lipid Metabolism
Hypoglycemic Agents
Drinking
Insulin Resistance
Blood Glucose
Triglycerides

Keywords

  • Diabetes mellitus
  • Diabetic nephropathy
  • Visfatin

ASJC Scopus subject areas

  • Nephrology
  • Cardiology and Cardiovascular Medicine

Cite this

Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice. / Kang, Young Sun; Lee, Mi Hwa; Song, Hye Kyoung; Kim, Jung Eun; Ghee, Jung Yeon; Cha, Jin Joo; Lee, Ji Eun; Kim, Hyun Wook; Han, Jee Young; Cha, Dae-Ryong.

In: Kidney and Blood Pressure Research, Vol. 41, No. 3, 01.06.2016, p. 311-324.

Research output: Contribution to journalArticle

Kang, Young Sun ; Lee, Mi Hwa ; Song, Hye Kyoung ; Kim, Jung Eun ; Ghee, Jung Yeon ; Cha, Jin Joo ; Lee, Ji Eun ; Kim, Hyun Wook ; Han, Jee Young ; Cha, Dae-Ryong. / Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice. In: Kidney and Blood Pressure Research. 2016 ; Vol. 41, No. 3. pp. 311-324.
@article{a03f3c182a234c1c8bd5c49441262941,
title = "Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice",
abstract = "Background/Aims: Visfatin is a known adipokine which may improve insulin resistance in obesity and have an anti-diabetic effect via the insulin receptor. We studied the effects of visfatin on diabetic nephropathy in type 2 diabetic mice. Methods: Diabetic male db/db mice were treated with intraperitoneal injections of visfatin. Basal parameters were measured in all mice and glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed in diabetic mice. The histopathological and molecular changes were evaluated in diabetic nephropathy. Results: Visfatin treatment had no effect on body weight, water and food intake, urinary volume, blood glucose, and HbA1c level. However, visfatin improved HOMA-IR, GTT, ITT and decreased plasma insulin and visfatin level, but not adiponectin level. Plasma cholesterol and triglyceride level were also improved by visfatin treatment. Significantly, visfatin decreased albuminuria in diabetic mice. Glomerulosclerotic change and mesangial expansion in the kidneys were significantly reduced. In addition, visfatin inhibited the expression of proinflammatory and profibrotic cytokines such as MCP-1, TGFβ1, type IV collagen, and PAI-1. The enzymes related to lipid metabolism in the kidney, HMG-CoAR was suppressed by visfatin treatment, whereas FXR and ABCA1 were significantly elevated by treatment. Conclusion: Visfatin might have a protective effect in diabetic nephropathy without the hypoglycemic effect.",
keywords = "Diabetes mellitus, Diabetic nephropathy, Visfatin",
author = "Kang, {Young Sun} and Lee, {Mi Hwa} and Song, {Hye Kyoung} and Kim, {Jung Eun} and Ghee, {Jung Yeon} and Cha, {Jin Joo} and Lee, {Ji Eun} and Kim, {Hyun Wook} and Han, {Jee Young} and Dae-Ryong Cha",
year = "2016",
month = "6",
day = "1",
doi = "10.1159/000443433",
language = "English",
volume = "41",
pages = "311--324",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice

AU - Kang, Young Sun

AU - Lee, Mi Hwa

AU - Song, Hye Kyoung

AU - Kim, Jung Eun

AU - Ghee, Jung Yeon

AU - Cha, Jin Joo

AU - Lee, Ji Eun

AU - Kim, Hyun Wook

AU - Han, Jee Young

AU - Cha, Dae-Ryong

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background/Aims: Visfatin is a known adipokine which may improve insulin resistance in obesity and have an anti-diabetic effect via the insulin receptor. We studied the effects of visfatin on diabetic nephropathy in type 2 diabetic mice. Methods: Diabetic male db/db mice were treated with intraperitoneal injections of visfatin. Basal parameters were measured in all mice and glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed in diabetic mice. The histopathological and molecular changes were evaluated in diabetic nephropathy. Results: Visfatin treatment had no effect on body weight, water and food intake, urinary volume, blood glucose, and HbA1c level. However, visfatin improved HOMA-IR, GTT, ITT and decreased plasma insulin and visfatin level, but not adiponectin level. Plasma cholesterol and triglyceride level were also improved by visfatin treatment. Significantly, visfatin decreased albuminuria in diabetic mice. Glomerulosclerotic change and mesangial expansion in the kidneys were significantly reduced. In addition, visfatin inhibited the expression of proinflammatory and profibrotic cytokines such as MCP-1, TGFβ1, type IV collagen, and PAI-1. The enzymes related to lipid metabolism in the kidney, HMG-CoAR was suppressed by visfatin treatment, whereas FXR and ABCA1 were significantly elevated by treatment. Conclusion: Visfatin might have a protective effect in diabetic nephropathy without the hypoglycemic effect.

AB - Background/Aims: Visfatin is a known adipokine which may improve insulin resistance in obesity and have an anti-diabetic effect via the insulin receptor. We studied the effects of visfatin on diabetic nephropathy in type 2 diabetic mice. Methods: Diabetic male db/db mice were treated with intraperitoneal injections of visfatin. Basal parameters were measured in all mice and glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed in diabetic mice. The histopathological and molecular changes were evaluated in diabetic nephropathy. Results: Visfatin treatment had no effect on body weight, water and food intake, urinary volume, blood glucose, and HbA1c level. However, visfatin improved HOMA-IR, GTT, ITT and decreased plasma insulin and visfatin level, but not adiponectin level. Plasma cholesterol and triglyceride level were also improved by visfatin treatment. Significantly, visfatin decreased albuminuria in diabetic mice. Glomerulosclerotic change and mesangial expansion in the kidneys were significantly reduced. In addition, visfatin inhibited the expression of proinflammatory and profibrotic cytokines such as MCP-1, TGFβ1, type IV collagen, and PAI-1. The enzymes related to lipid metabolism in the kidney, HMG-CoAR was suppressed by visfatin treatment, whereas FXR and ABCA1 were significantly elevated by treatment. Conclusion: Visfatin might have a protective effect in diabetic nephropathy without the hypoglycemic effect.

KW - Diabetes mellitus

KW - Diabetic nephropathy

KW - Visfatin

UR - http://www.scopus.com/inward/record.url?scp=84973121538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973121538&partnerID=8YFLogxK

U2 - 10.1159/000443433

DO - 10.1159/000443433

M3 - Article

C2 - 27221663

AN - SCOPUS:84973121538

VL - 41

SP - 311

EP - 324

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 3

ER -